* Based on management’s market analysis studies and expected adoption rates.
Sources And More Key Details: Company Website. Company Presentation.
As mentioned above, CVKD has several potential breakout catalysts to focus in on right now. Check them out:
No. 1 CVKD Potential Catalyst - Volatility Could Be Significant Based On CVKD's Low Float Size
According to the Yahoo Finance website, CVKD has a very low float.
The website reports this profile to have approximately 3.74Mn shares in its float.
Why is that important? It's important on one crucial level. Volatility.
Could positive company news before the end of this year help provide a near term spark?
No. 2 CVKD Potential Catalyst - Huge August News Brings In New Addressable Market Potential
On two separate occasions this past month, CVKD announced different health issues that the company's flagship drug candidate, tecarfarin, could replace warfarin as the preferred treatment.
8/30/23 - Cadrenal Therapeutics Expands Evaluation of Tecarfarin for Patients with Antiphospholipid Syndrome (APS)
"Antiphospholipid syndrome is a rare medical condition and blood clotting disorder affecting approximately 167k patients in the United States which currently has no cure. Effective anticoagulation (with blood thinners) should prevent health problems caused by the condition with the goal of treatment to prevent blood clots from forming and to keep existing clots from getting larger," commented Douglas Losordo, Chief Medical Officer of Cadrenal Therapeutics. "However, the only widely prescribed anticoagulant approved for this patient population is warfarin, a 70-year-old drug, which fails to achieve sufficiently reliable anticoagulation due to the way in which it is metabolized. We believe tecarfarin, which is specifically designed to solve warfarin's metabolism problem by using an alternate pathway, could provide improved outcomes for this patient population. Tecarfarin's metabolic pathway is abundant and essentially insaturable, which results in a reliable, stable pharmacokinetic profile."
8/1/23 - Cadrenal Therapeutics Expands Focus for Tecarfarin to Patients with Implanted Medical Devices for Heart Diseases
"The goal for Cadrenal is to advance tecarfarin in targeted indications where Vitamin K antagonists (warfarin) are prescribed yet have failed to achieve sufficiently reliable anticoagulation," commented Quang Pham, CEO of Cadrenal Therapeutics. "Patients with implanted medical devices such as left ventricular assist devices (LVADs) struggle with warfarin due to the way in which it is metabolized, resulting in suboptimal anticoagulation. Tecarfarin is specifically designed to solve warfarin's metabolism problem via an alternate pathway that is abundant and essentially insaturable, providing a much more reliable pharmacokinetic profile. We look forward to expanding our focus for tecarfarin within this patient population."
No. 3 CVKD Potential Catalyst - 2023's Bombshell News (U.S. FDA Grants Fast Track Designation To Tecarfarin)
Cadrenal Therapeutics (Nasdaq: CVKD) Granted FDA Fast Track Designation for Tecarfarin for Prevention of Systemic Thromboembolism of Cardiac Origin in Patients with End-Stage Renal Disease and Atrial Fibrillation
PONTE VEDRA, Fla., Jan. 23, 2023 /PRNewswire/ — Cadrenal Therapeutics (Nasdaq: CVKD), a biopharmaceutical company focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug designation, announced today that the U.S. Food and Drug Administration (FDA) has granted a Fast Track designation to tecarfarin for the prevention of systemic thromboembolism, more commonly referred to as blood clots, of cardiac origin in patients with end-stage renal disease (ESRD) and atrial fibrillation (AFib).
"The Fast Track designation for tecarfarin is an important milestone in the development of this therapy and highlights the importance of finding an effective treatment for the prevention of blood clots of cardiac origin in patients with ESRD and AFib," said Quang Pham, Chief Executive Officer of Cadrenal. "We look forward to working closely with the FDA to evaluate this therapy as a potential new treatment option for this underserved patient population."
Read the full article here.
No. 4 CVKD Potential Catalyst - Exposure Could Be Growing As CVKD Joins The Nasdaq CM In 2023
Cadrenal Therapeutics (Nasdaq: CVKD) Announces Closing of Initial Public Offering
PONTE VEDRA, Fla., Jan. 24, 2023 /PRNewswire/ — Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug indication, today announced the closing of its initial public offering of 14Mn shares of common st-ock at a public offering price of $5.00 per share for gross proceeds of $7Mn, before deducting underwriting discounts and estimated offering expenses. ...
The Company's common st-ock began trading on the Nasdaq Capital Market on January 20, 2023, under the symbol "CVKD."
Read the full article here.
No. 5 CVKD Potential Catalyst - Company Strengthens Board With Industry Leader (Former CCO Of Arena Pharmaceuticals)
Cadrenal Therapeutics Announces Appointment of Robert Lisicki to Board of Directors
PONTE VEDRA, Fla., July 24, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc., ("Cadrenal" or the "Company") (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) for certain rare medical conditions, today announced the appointment of Robert Lisicki to its Board of Directors and Compensation and Nomination/Governance Committees. Lisicki brings over 25 years of experience in the pharma/biotech sector, including as the Chief Commercial Officer of Arena Pharmaceuticals, where he provided global visionary leadership for the $6.7Bn growth-stage biopharmaceutical company through their acquisition by Pfizer in March 2022.
"Robert is a highly accomplished executive with a proven track record leading rapidly growing clinical-stage public companies, including successes with cardiovascular therapeutics and strong relationships with life sciences investors. His experience in developing collaborative research agreements with large pharma across multiple therapeutic areas will be a valuable asset as we look to advance tecarfarin," said Quang Pham, Chairman and CEO of Cadrenal. "I look forward to leaning on his executive experience and commercial vision as a member of the Cadrenal board."
During his time as Chief Commercial Officer at Arena Pharmaceuticals, Lisicki had a leadership role in more than $8Bn in M&A activities. He regularly interacted with FDA, EMA, and PDMA on study and protocol designs.
"I believe Cadrenal Therapeutics is developing a novel and potentially paradigm-changing therapeutic," said Robert Lisicki. "I look forward to working with the team to advance the development and value that Tecarfarin may bring to serious and life-threatening diseases."
Lisicki will occupy a newly created seat on the Cadrenal Board of Directors.
Read the full article here.
CVKD Recap - 5 Must-See Potential Breakout Catalysts Right Now
No. 1 - Volatility Could Be Significant Based On CVKD's Low Float Size
No. 2 - Huge August News Brings In New Addressable Market Potential
No. 3 - 2023's Bombshell News (U.S. FDA Grants Fast Track Designation To Tecarfarin)
No. 4 - Exposure Could Be Growing As CVKD Joins The Nasdaq CM In 2023
No. 5 - Company Strengthens Board With Industry Leader (Former CCO Of Arena Pharmaceuticals)
Coverage is officially initiated on CVKD. When time allows, do this: